FGF21 analogs have been shown to ameliorate dyslipidemia and enhance adiponectin levels in individuals with obesity and T2D, though their effects on glycemic control remain limited [36]. This evidence concerns the gene ADIPOQ and obesity due to melanocortin 4 receptor deficiency.